Clinically Relevant Biomarker Discovery in High-Risk Recurrent Neuroblastoma

Abstract excerpt

Neuroblastoma is a pediatric cancer of the developing sympathetic nervous system. High-risk neuroblastoma patients typically undergo an initial remission in response to treatment, followed by recurrence of aggressive tumors that have become refractory to further treatment. The need for biomarkers that can select patients not responding well to therapy in an early phase is therefore needed. In this study, we used...

Topics

Share this publication in a Topic to start or enrich a Post.

• Share to Cancer, Hypoxia, and Metabolism
• Share to Neuroblastoma Research and Treatments
• Share to Signaling Pathways in Disease